ANIK - Anika Therapeutics Inc Stock Price, Fair Value and News

25.73USD-0.11 (-0.43%)Delayed as of 22 Apr 2024, 12:54 pm ET

Market Summary

USD25.73-0.11

Delayedas of 22 Apr 2024, 12:54 pm

-0.43%

ANIK Stock Price

View Fullscreen

ANIK RSI Chart

ANIK Valuation

Market Cap

383.7M

Price/Earnings (Trailing)

-4.64

Price/Sales (Trailing)

2.3

EV/EBITDA

-3.94

Price/Free Cashflow

-53.18

ANIK Price/Sales (Trailing)

ANIK Profitability

EBT Margin

-51.20%

Return on Equity

-38.95%

Return on Assets

-30.55%

Free Cashflow Yield

-1.88%

ANIK Fundamentals

ANIK Revenue

Revenue (TTM)

166.7M

Rev. Growth (Yr)

8.45%

Rev. Growth (Qtr)

3.63%

ANIK Earnings

Earnings (TTM)

-82.7M

Earnings Growth (Yr)

-1.2K%

Earnings Growth (Qtr)

-858.03%

Breaking Down ANIK Revenue

52 Week Range

16.5428.13

(Low)(High)

Last 7 days

3.2%

Last 30 days

0.9%

Last 90 days

16.1%

Trailing 12 Months

-5.2%

How does ANIK drawdown profile look like?

ANIK Financial Health

Current Ratio

5.26

Debt/Equity

0.12

Debt/Cashflow

-0.07

ANIK Investor Care

Shares Dilution (1Y)

1.48%

Diluted EPS (TTM)

-5.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	157.5M	162.1M	163.3M	166.7M
2022	150.2M	151.7M	152.4M	156.2M
2021	129.4M	136.8M	144.7M	147.8M
2020	125.3M	125.5M	127.5M	130.5M
2019	109.0M	108.9M	111.8M	114.6M
2018	111.3M	108.4M	108.0M	105.6M
2017	104.5M	111.4M	112.8M	113.4M
2016	99.8M	103.4M	105.5M	103.4M
2015	87.1M	83.7M	85.4M	93.0M
2014	93.8M	99.3M	103.6M	105.6M
2013	72.2M	73.4M	76.4M	75.1M
2012	67.4M	70.9M	67.2M	71.4M
2011	54.8M	56.5M	61.1M	64.8M
2010	0	45.3M	50.4M	55.6M
2009	0	0	0	40.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Anika Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	blanchard cheryl r	acquired	-	-	64,480	president, ceo, director
Mar 11, 2024	nunes anne	sold (taxes)	-44,000	25.5818	-1,720	svp, chief operations officer
Mar 11, 2024	nunes anne	acquired	-	-	5,856	svp, chief operations officer
Mar 11, 2024	levitz michael l	acquired	-	-	19,201	evp, cfo, treasurer
Mar 11, 2024	colleran david	acquired	-	-	16,809	evp, general counsel, corp sec
Mar 11, 2024	levitz michael l	sold (taxes)	-144,284	25.5913	-5,638	evp, cfo, treasurer
Mar 11, 2024	colleran david	sold (taxes)	-126,306	25.5887	-4,936	evp, general counsel, corp sec
Mar 11, 2024	blanchard cheryl r	sold (taxes)	-716,629	25.6122	-27,980	president, ceo, director
Oct 01, 2023	nunes anne	acquired	-	-	2,491	svp, chief operations officer
Oct 01, 2023	nunes anne	sold (taxes)	-13,637	18.63	-732	svp, chief operations officer

Which funds bought or sold ANIK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	27.95	501,949	1,657,860	-%
Apr 17, 2024	BARRETT & COMPANY, INC.	unchanged	-	712	6,604	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	unchanged	-	38,141	353,568	-%
Apr 05, 2024	CWM, LLC	unchanged	-	1,000	7,000	-%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	334	4,521	-%
Apr 03, 2024	Versant Capital Management, Inc	unchanged	-	27.00	254	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-54.28	-4,739	5,937	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-0.49	3,009,200	17,313,300	-%
Mar 05, 2024	Fisher Asset Management, LLC	reduced	-5.17	116,422	875,128	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	95.73	2,122,180	3,659,230	-%

Are Funds Buying or Selling ANIK?

Are funds buying ANIK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANIK

No. of Funds

Unveiling Anika Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	blackrock inc.	10.7%	1,561,112	SC 13G/A
Mar 06, 2024	caligan partners lp	9.7%	1,423,493	SC 13D/A
Feb 13, 2024	vanguard group inc	5.22%	764,045	SC 13G/A
Feb 09, 2024	dimensional fund advisors lp	5.6%	821,452	SC 13G/A
Feb 09, 2024	trigran investments, inc.	14.6%	2,139,054	SC 13G/A
Jan 24, 2024	blackrock inc.	9.5%	1,383,877	SC 13G/A
Jan 22, 2024	state street corp	2.11%	309,041	SC 13G/A
Oct 06, 2023	blackrock inc.	9.7%	1,416,135	SC 13G/A
Sep 11, 2023	caligan partners lp	7.4%	1,081,360	SC 13D/A
Aug 17, 2023	caligan partners lp	6.2%	902,086	SC 13D

Recent SEC filings of Anika Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	SC 13G/A	Major Ownership Report
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	10-K	Annual Report
Mar 13, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading

Peers (Alternatives to Anika Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.2B	40.1B	-3.77%	-2.76%	32.53	4.64	-8.12%	-17.45%
BDX	67.7B	19.5B	-1.53%	-10.57%	53.87	3.47	4.02%	-22.04%
ALGN	22.5B	3.9B	-9.16%	-15.16%	50.45	5.81	3.42%	23.09%
BAX	20.0B	14.8B	-5.62%	-8.72%	7.55	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.49%	17.01%	32.33	2.64	4.97%	18.89%
HSIC	9.1B	12.3B	-5.22%	-14.61%	21.9	0.74	-2.44%	-22.68%
BIO	8.2B	2.7B	-16.90%	-39.13%	-12.81	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.41%	-25.34%	-47.02	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-2.66%	12.41%	-562.64	9.32	33.86%	89.83%
PDCO	2.3B	6.6B	-4.93%	-3.92%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-14.38%	-20.49%	-1.83	0.39	7.73%	-1066.14%
ANIK	383.7M	166.7M	0.86%	-5.21%	-4.64	2.3	6.67%	-456.34%
ANGO	250.7M	324.0M	11.81%	-29.38%	-1.3	0.77	-3.19%	-337.41%
APYX	45.7M	52.3M	-28.65%	-55.25%	-2.44	0.87	17.61%	19.28%
AEMD	3.8M	3.7M	-10.98%	147.46%	-0.31	1.02	5.77%	8.23%

Anika Therapeutics Inc News

Latest updates

Anika Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	3.6%	42,971,000	41,465,000	44,302,000	37,924,000	39,622,000	40,264,000	39,657,000	36,693,000	35,821,000	39,536,000	38,145,000	34,292,000	32,688,000	31,694,000	30,678,000	35,397,000	29,772,000	29,697,000	30,418,000	24,723,000	26,956,000
Gross Profit	5.6%	26,329,000	24,944,000	28,972,000	22,843,000	24,131,000	22,779,000	24,862,000	21,804,000	18,134,000	23,023,000	20,812,000	20,974,000	16,745,000	17,343,000	13,742,000	21,197,000	21,123,000	23,746,000	23,582,000	17,412,000	18,834,000
Costs and Expenses	176.3%	90,110,000	32,618,000	32,603,000	35,396,000	30,798,000	28,577,000	28,243,000	25,358,000	27,257,000	21,723,000	11,632,000	19,716,000	34,697,000	25,270,000	23,278,000	14,103,000	-3,777,000	17,648,000	18,503,000	19,241,000	-14,086,000
S&GA Expenses	-18.1%	20,335,000	24,827,000	23,689,000	26,996,000	23,049,000	21,276,000	21,268,000	19,201,000	20,432,000	17,500,000	17,989,000	18,175,000	15,179,000	15,903,000	14,550,000	14,431,000	12,237,000	7,539,000	7,502,000	7,672,000	6,129,000
R&D Expenses	-2.6%	7,585,000	7,791,000	8,914,000	8,400,000	7,749,000	7,301,000	6,975,000	6,157,000	6,000,000	7,673,000	7,293,000	6,361,000	7,632,000	5,217,000	4,532,000	6,050,000	4,084,000	4,158,000	4,165,000	4,258,000	4,064,000
EBITDA Margin	-251.6%	-0.47	-0.13	-0.13	-0.13	-0.08	-0.10	-0.05	0.03	0.06	0.00	-0.10	-0.23	-	-	-	-	-	-	-	-	-
Income Taxes	61.4%	-178,500	-463,000	-300,000	-1,700,000	-1,470,500	-1,187,000	-442,000	-800,000	-3,404,000	694,000	2,600,000	-1,600,000	-2,503,000	-1,700,000	-1,997,000	1,580,000	1,117,500	3,331,000	3,000,000	1,473,000	2,595,500
Earnings Before Taxes	-797.9%	-63,204,000	-7,039,000	-3,070,000	-12,014,000	-6,391,000	-5,362,000	-3,285,000	-3,708,000	-9,170,000	1,252,000	9,130,000	1,215,000	-18,137,000	-8,155,000	-9,705,000	7,373,000	5,162,000	12,531,000	12,448,000	5,980,000	10,313,000
EBT Margin	-193.2%	-0.51	-0.17	-0.17	-0.17	-0.12	-0.14	-0.10	-0.02	0.02	-0.05	-0.12	-0.27	-	-	-	-	-	-	-	-	-
Net Income	-858.0%	-63,000,000	-6,576,000	-2,741,000	-10,350,000	-4,908,000	-4,175,000	-2,843,000	-2,933,000	-5,793,000	558,000	6,531,000	2,838,000	-15,657,000	-6,411,000	-7,708,000	5,793,000	4,051,000	9,200,000	9,435,000	4,507,000	7,717,000
Net Income Margin	-229.6%	-0.50	-0.15	-0.14	-0.14	-0.10	-0.10	-0.07	-0.01	0.03	-0.04	-0.09	-0.21	-	-	-	-	-	-	-	-	-
Free Cashflow	-68.7%	1,798,000	5,744,000	-9,750,000	-5,007,000	-2,048,000	1,018,000	1,148,000	-3,195,000	3,345,000	778,000	1,979,000	-2,848,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-17.5%	271	328	329	339	349	348	354	342	348	353	363	362	366	416	441	399	331	320	287	307	279
Current Assets	4.2%	163	157	152	160	170	168	168	165	169	166	178	173	177	202	221	161	234	224	190	210	203
Cash Equivalents	3.1%	73.00	71.00	65.00	80.00	86.00	88.00	91.00	90.00	94.00	91.00	97.00	95.00	96.00	104	117	66.00	157	103	69.00	96.00	89.00
Inventory	6.1%	46.00	44.00	43.00	41.00	40.00	37.00	35.00	35.00	36.00	35.00	43.00	43.00	46.00	48.00	46.00	43.00	22.00	25.00	23.00	23.00	21.00
Net PPE	0.6%	46.00	46.00	48.00	49.00	48.00	47.00	48.00	48.00	48.00	49.00	50.00	49.00	51.00	52.00	53.00	54.00	51.00	52.00	53.00	53.00	54.00
Goodwill	4.4%	8.00	7.00	7.00	7.00	7.00	7.00	7.00	8.00	8.00	8.00	8.00	8.00	8.00	32.00	34.00	34.00	8.00	7.00	8.00	8.00	8.00
Current Liabilities	10.7%	31.00	28.00	23.00	29.00	28.00	26.00	29.00	27.00	30.00	29.00	41.00	47.00	37.00	31.00	28.00	26.00	16.00	11.00	10.00	12.00	11.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.00	50.00	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.00	50.00	-	-	-	-	-	-
Shareholder's Equity	-21.5%	212	270	274	278	286	285	286	286	287	290	287	277	272	284	288	294	288	282	251	269	264
Retained Earnings	-33.0%	128	191	198	200	211	216	220	223	226	231	231	224	221	237	244	251	245	241	232	223	218
Additional Paid-In Capital	4.8%	90.00	86.00	82.00	83.00	81.00	77.00	73.00	69.00	67.00	64.00	61.00	57.00	55.00	53.00	51.00	48.00	49.00	46.00	24.00	52.00	51.00
Accumulated Depreciation	-	48.00	-	-	-	46.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.2%	15.00	15.00	15.00	15.00	15.00	15.00	15.00	14.00	14.00	14.00	14.00	14.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	370	-	-	-	322	-	-	-	620	-	-	-	531	-	-	-	570	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-43.9%	3,638	6,485	-8,293	-3,618	481	2,709	3,088	-1,869	4,472	2,062	4,294	-2,431	2,587	5,865	3,568	1,045	13,022	10,051	5,470	8,462	10,013
Share Based Compensation	7.1%	3,815	3,561	4,150	3,717	3,813	3,876	4,081	2,545	3,166	2,863	2,797	2,259	1,433	1,920	2,240	-207	1,947	1,311	1,443	1,386	982
Cashflow From Investing	-148.3%	-1,840	-741	-1,457	-1,389	-2,529	-1,691	-1,940	-1,326	-1,240	-1,295	-2,317	1,734	16,809	6,729	-2,299	-92,503	41,024	2,100	-1,516	-1,917	-2,581
Cashflow From Financing	410.9%	342	-110	-4,943	-1,613	667	-4,611	-46.00	-862	60.00	-6,982	594	-451	-28,112	-25,179	49,658	-141	278	21,699	-30,000	-119	-55.00
Buy Backs	-	-	-	5,050	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	30,000	-	-

ANIK Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue	$ 166,662	$ 156,236	$ 147,794
Cost of revenue	63,574	62,660	64,851
Gross profit	103,088	93,576	82,943
Operating expenses:
Research & development	32,690	28,182	27,327
Selling, general & administrative	95,847	84,794	74,096
Impairment of intangible assets	62,190	0	0
Change in fair value of contingent consideration	0	0	(21,095)
Total operating expenses	190,727	112,976	80,328
(Loss) income from operations	(87,639)	(19,400)	2,615
Interest and other income (expense), net	2,312	654	(188)
(Loss) income before income taxes	(85,327)	(18,746)	2,427
Benefit from for income taxes	(2,660)	(3,887)	(1,707)
Net (loss) income	$ (82,667)	$ (14,859)	$ 4,134
Basic (in dollars per share)	$ (5.64)	$ (1.02)	$ 0.29
Diluted (in dollars per share)	$ (5.64)	$ (1.02)	$ 0.28
Basic (in shares)	14,656	14,561	14,401
Diluted (in shares)	14,656	14,561	14,634
Net (loss) income	$ (82,667)	$ (14,859)	$ 4,134
Foreign currency translation adjustment	500	(725)	(1,176)
Comprehensive (loss) income	$ (82,167)	$ (15,584)	$ 2,958

ANIK Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 72,867	$ 86,327
Accounts receivable, net	35,961	34,627
Inventories	46,386	39,765
Prepaid expenses and other current assets	8,095	8,828
Total current assets	163,309	169,547
Property and equipment, net	46,198	48,279
Right-of-use assets	28,767	30,696
Other long-term assets	18,672	17,219
Deferred tax assets	1,489	1,449
Intangible assets, net	4,626	74,599
Goodwill	7,571	7,339
Total assets	270,632	349,128
Current liabilities:
Accounts payable	9,860	9,074
Accrued expenses and other current liabilities	21,199	18,840
Total current liabilities	31,059	27,914
Other long-term liabilities	404	398
Deferred tax liability	0	6,436
Lease liabilities	26,904	28,817
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022, respectively		0
Common stock, $.01 par value; 90,000 shares authorized, 14,848 issued and 14,660 outstanding and 14,625 shares issued and outstanding at December 31, 2023 and 2022, respectively	147	146
Additional paid-in-capital	90,009	81,141
Accumulated other comprehensive loss	(5,943)	(6,443)
Retained earnings	128,052	210,719
Total stockholders’ equity	212,265	285,563
Total liabilities and stockholders’ equity	$ 270,632	$ 349,128

About Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

CEO	Dr. Cheryl Renee Blanchard Ph.D.
WEBSITE	anikatherapeutics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	345

Anika Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Anika Therapeutics Inc? What does ANIK stand for in stocks?

ANIK is the stock ticker symbol of Anika Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anika Therapeutics Inc (ANIK)?

As of Fri Apr 19 2024, market cap of Anika Therapeutics Inc is 383.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIK stock?

You can check ANIK's fair value in chart for subscribers.

What is the fair value of ANIK stock?

You can check ANIK's fair value in chart for subscribers. The fair value of Anika Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anika Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANIK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anika Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ANIK is over valued or under valued. Whether Anika Therapeutics Inc is cheap or expensive depends on the assumptions which impact Anika Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIK.

What is Anika Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, ANIK's PE ratio (Price to Earnings) is -4.64 and Price to Sales (PS) ratio is 2.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Anika Therapeutics Inc's stock?

In the past 10 years, Anika Therapeutics Inc has provided -0.048 (multiply by 100 for percentage) rate of return.